Exposed: 10 CENT Crypto to Explode April 20th?

The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…

John Hamer Biography and Net Worth

Director of AbCellera Biologics

John is a Managing General Partner at DCVC Bio, a San Francisco venture capital fund focused on building the next generation of life science companies. John has held positions as Managing Partner and Founder of Monsanto Growth Ventures, Managing Director and Entrepreneur-in-Residence at Burrill & Co. Prior to venture capital, John held senior management positions at Paradigm Genetics Inc./Icoria, (NASDAQ::PDGM) including CSO, CEO and EVP for Business Development. John has a PhD in Microbiology from the University of California, Davis and was Professor of Biological Sciences at Purdue University where he was a Packard Fellow and NSF Presidential Faculty Fellow.

How do I contact John Hamer?: The corporate mailing address for Dr. Hamer and other AbCellera Biologics executives is , , . AbCellera Biologics can also be reached via phone at 604-559-9005 and via email at [email protected]. Learn More on John Hamer's contact information.
Has John Hamer been buying or selling shares of AbCellera Biologics?: John Hamer has not been actively trading shares of AbCellera Biologics during the past quarter. Most recently, John Hamer sold 162,649 shares of the business's stock in a transaction on Tuesday, August 31st. The shares were sold at an average price of $16.95, for a transaction totalling $2,756,900.55. Learn More on John Hamer's trading history.
Who are AbCellera Biologics' active insiders?: AbCellera Biologics' insider roster includes Andrew Booth (CFO), John Hamer (Director), Carl Hansen (CEO), Michael Hayden (Director), Veronique Lecault (COO), Andrew Lo (Director), and John Montalbano (Director). Learn More on AbCellera Biologics' active insiders.
Are insiders buying or selling shares of AbCellera Biologics?: During the last year, AbCellera Biologics insiders bought shares 2 times. They purchased a total of 167,500 shares worth more than $1,096,885.00. The most recent insider tranaction occured on May, 26th when CFO Andrew Booth bought 14,500 shares worth more than $99,325.00. Insiders at AbCellera Biologics own 32.5% of the company. Learn More about insider trades at AbCellera Biologics.
Information on this page was last updated on 5/26/2023.

John Hamer Insider Trading History at AbCellera Biologics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/31/2021	Sell	162,649	$16.95	$2,756,900.55

John Hamer Buying and Selling Activity at AbCellera Biologics

AbCellera Biologics Company Overview

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets, as well as strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Today's Range

Now: $3.75

$3.64

$3.80

50 Day Range

MA: $4.59

$3.63

$5.34

2 Week Range

Now: $3.75

$3.62

$8.05

Volume

1,287,649 shs

Average Volume

1,369,289 shs

Market Capitalization

$1.10 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.36